Quick Answer
Sodium Bicarbonate Recovery Randomized Trial has evidence relevant to strength of evidence and what the studies can or cannot prove, but conclusions should stay close to the cited sources. One representative finding is: It is associated with significant morbidity and mortality due to a profound change in its epidemiological profile - multifactorial in origin, often septic, and associated with other organ failures.
Key Takeaways
- 01It is associated with significant morbidity and mortality due to a profound change in its epidemiological profile - multifactorial in origin, often septic, and associated with other organ failures. [Kada K (2026)]
- 02Acute kidney injury (AKI) is common in hospitalized patients, and its incidence is rising sharply in intensive care units. [Kada K (2026)]
- 03Seventy of 109 patients (64%) in the “on-demand” group achieved recovery compared with 55 of 109 patients (50%) in the conventional group (absolute risk difference 13.8%; 95% CI, 0.8%-26.8%; P=.04). [Garsuta Cani Greg L. (2026)]
- 04The “on-demand” group received significantly fewer weekly sessions (median 1.8 vs 3.1) and experienced fewer episodes of dialysis-associated hypotension (69 vs 97 events). [Garsuta Cani Greg L. (2026)]
The current Migaku evidence database contains 2 reusable source documents for Sodium Bicarbonate Recovery Randomized Trial. This answer focuses on strength of evidence and what the studies can or cannot prove.
- It is associated with significant morbidity and mortality due to a profound change in its epidemiological profile - multifactorial in origin, often septic, and associated with other organ failures. [Kada K (2026); evidence level 4]
- Acute kidney injury (AKI) is common in hospitalized patients, and its incidence is rising sharply in intensive care units. [Kada K (2026); evidence level 4]
- Seventy of 109 patients (64%) in the “on-demand” group achieved recovery compared with 55 of 109 patients (50%) in the conventional group (absolute risk difference 13.8%; 95% CI, 0.8%-26.8%; P=.04). [Garsuta Cani Greg L. (2026); evidence level 4]
- The “on-demand” group received significantly fewer weekly sessions (median 1.8 vs 3.1) and experienced fewer episodes of dialysis-associated hypotension (69 vs 97 events). [Garsuta Cani Greg L. (2026); evidence level 4]
- There were no significant differences in mortality or severe adverse events (e.g., arrhythmias, severe electrolyte derangements), indicating that the reduced frequency did not compromise patient safety. [Garsuta Cani Greg L. (2026); evidence level 4]
Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording.
This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.
Sources